Efficacy and Mechanism of Hypofractionation Radiotherapy Combined with PD-1 Inhibitors in a Model of Head and Neck Melanoma

Gaofei Yin,Wei Guo,Xiaohong Chen,Yang Zhang,Zhigang Huang

DOI: https://doi.org/10.3390/cancers16030675

2024-02-06

Cancers

Abstract:Head and neck mucosal melanoma is one of the most common types of melanoma in China, but the prognosis is worse than other types, and there is no effective treatment plan to improve patient survival. This study analyzes the efficacy of hypofractionation radiotherapy combined with PD-1 inhibitor in the treatment of head and neck mucosal melanoma, as well as its impact on the tumor immune microenvironment. NPSG mice were used to construct a humanized bilateral lesion tumor model of the humanized immune system. The models were divided into an RT (8 Gy)+anti PD-1 group, an RT (2 GyX4)+anti PD-1 group, an Anti PD-1 group, an RT (8 Gy) group, and a blank group. Differences in efficacy and immune cells in blood, lymph nodes, and tumor tissues were compared between different treatment groups. The treatment effect of RT (8 Gy)+anti PD-1 was better than the other groups with a tumor growth inhibition value (TGI) over 60%. Significant recruitment and activation of CD8+T cells were found in the blood, lymph nodes, and tumor tissues and significantly inhibited the level of PD-1+CD8+T cells in the group of RT (8 Gy)+anti PD-1. This study confirmed the efficacy of hypofractionation radiotherapy combined with PD-1 inhibitors, which can inhibit tumor growth and produce distant effects. The appearance of a distant effect is related to the enhancement in the number and activity of CD8+T cells in the local tumor and peripheral blood and lymph nodes. This study confirms the therapeutic and immune regulatory effect of hypofractionation radiotherapy combined with PD-1 inhibitors.

oncology

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve

This paper aims to explore the efficacy of hypofractionation radiotherapy combined with PD-1 inhibitors in the treatment of head and neck mucosal melanoma and its impact on the tumor immune microenvironment.

Specifically, the study constructs an immune-humanized mouse model to verify the following points:
1. **Efficacy Verification**: The effectiveness of the combination therapy of hypofractionation radiotherapy and PD-1 inhibitors on head and neck mucosal melanoma.
2. **Immune Impact**: The specific impact of the combination therapy on T cell immune response.
3. **Preclinical Data Reference**: Providing preclinical data reference for subsequent clinical treatments.

The study results show that the RT (8 Gy) + anti PD-1 group has the highest tumor growth inhibition rate, reaching 63.5%, which is significantly better than other groups, and can significantly activate CD8+ T cells, thereby producing distal effects. In addition, this combination therapy can effectively improve local and distal immune status.